The Lifestyle Drugs Outlook To 2008: Unlocking New Value In Well-Being

The lifestyle drugs market is currently worth a phenomenal $23bn to boost its value, pharmaceutical companies are actively searching for new lifestyle products and conditions. The Lifestyle Drugs Outlook to 2008: Unlocking new value in well-being, provides a timely market update, examining leading products and pipeline prospects in seven key lifestyle drug sectors, and is supported by forecasts to 2008. Today's R&D is influenced as much by commercial unmet needs as it is by clinical opportunities and chance. Pharmaceutical companies must react quickly to these needs if they are to reap greater financial returns. This report can help you to assess the premium associated with different lifestyle drug markets and identify the potential for higher volume sales. Armed with this information your company can formulate winning lifestyle drug development and marketing strategies, and secure a strong competitive position within this market.

Executive Summary
The new premium pharmaceutical environment
Depression
Oral contraception
Sexual dysfunction
Smoking cessation
Obesity
Alopecia
Skin aging

Chapter 1 The new premium pharmaceutical environment
Summary
Introduction
Defining and delimiting the lifestyle drug market
How do I know if I have a lifestyle drug in my portfolio?
Social characteristics
Disease characteristics
Product characteristics
Summary
Segmentation of the global lifestyle drug market in 2002
Attraction of the lifestyle drug market for pharma
Optimizing returns on R&D
Innovation is more sustainable than patent defense
Consumers as surrogate sales reps
High demand upon launch
Ability to create new markets
Drivers of demand for lifestyle drugs
Demographic trends: an aging population
Growth in disposable income
Direct-to-consumer marketing
Increasing consumer health awareness
Rise in branding activities
Barriers to lifestyle drug market growth
Demonstrating value-for-money to payors the road to rationing
Models of lifestyle drug reimbursement: Viagra as a case example
UK, post-NICE: ‘exclusive rationing of lifestyle drugs
Australia’s hard-line approach
Recommendations for securing reimbursement of lifestyle drugs
Drug abuse and misuse
Loss of corporate control over brand

Chapter 2 Depression
Summary
Overview of depression
Pathophysiology and etiology
Types of depression
Prevalence
Drug therapy
Market analysis: leading and new product sales to 2008
Paxil/Seroxat (paroxetine)
Zoloft (sertraline)
Effexor (venlafaxine)
Lexapro (escitalopram)
Outlook for the depression market
Focus on unmet therapeutic needs
Pipeline analysis
Cymbalta (duloxetine)
Variza (gepirone)
Sunepitron
Sanofi-Synthélabos novel antidepressant pipeline

Chapter 3 Oral contraception
Summary
Overview of oral contraception
The female reproductive population
Drug therapy
Market analysis: leading company and product sales to 2008
Johnson & Johnson
OrthoTri-Cyclen and Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol)
Wyeth
Schering AG
Diane 35 (ethinylestradiol + cyproterone acetate)
Yasmin (drospirenone + ethinylestradiol)
Organon
Outlook for the oral contraception market
Focus on improving compliance
Overcoming perceived safety concerns
Multiple indications are key to success
Pipeline analysis
Seasonale (ethinyl estradiol + levonorgestrel)
Yasmin 20/Yasmin Lo (drospirenone + ethinylestradiol)
Trimegestone/ethinyl estradiol
ORG 30659 and ORG 30659/ethinyl estradiol
Chapter 4 Sexual dysfunction
Summary male sexual dysfunction
Summary female sexual dysfunction
Male sexual dysfunction
Pathophysiology and etiology
Loss of libido
Erectile dysfunction
Priapism
Peyronies disease
Premature and delayed ejaculation
Prevalence
Drug therapy
Market analysis: leading and new product sales to 2008
Viagra (sildenafil)
Cialis (tadalafil)
Levitra/Nuviva (vardenafil)
Uprima (apomorphine)
Outlook for the male sexual dysfunction market
Improving compliance with on demand erections
Expanding the patient pool
Focus on niche groups: diabetics and cardiovascular disease
Pipeline analysis
Female sexual dysfunction
Pathophysiology and etiology
Prevalence
Drug therapy
Outlook for the female sexual dysfunction market
Lack of diagnostic tools presents major barrier to drug development
Increasing presentation rates
Pipeline analysis

Chapter 5 Smoking cessation
Summary
Overview of smoking cessation
Pathophysiology
Prevalence
Drug therapy
Market analysis: Zybans sales to 2008
Outlook for the smoking cessation market
Unmet needs
Pipeline analysis
Zyban XL (bupropion)
Rimonabant
TA-NIC
NicVAX

Chapter 6 Obesity
Summary
Overview of obesity
Definition of obesity
Measuring and diagnosing obesity
Pathophysiology and etiology
Age and gender influence
Genetic influence
Nutritional influence
Prevalence
Countering the trend government action
Drug therapy
Market analysis: leading product sales to 2008
Xenical (orlistat)
Reductil/Meridia (sibutramine)
Outlook for the obesity market
Improving long-term drug safety
Pipeline analysis
Topamax (topiramate)
Axokine
P57

Chapter 7 Alopecia
Summary
Overview of alopecia
Pathophysiology and etiology
Types of alopecia
Alopecia areata
Androgenetic alopecia
Anagen effluvium
Telogen effluvium
Scarring alopecia
Self-induced alopecia
Other causes
Prevalence
Drug therapy
Market analysis: leading product sales to 2008
Propecia (finasteride)
Rogaine (minoxidil)
Outlook for the alopecia market
Pipeline analysis
Avodart (dutasteride)

Chapter 8 Skin aging
Summary
Overview of skin aging
Pathophysiology and etiology
Prevalence
Drug therapy
Market analysis: leading product sales to 2008
Renova (tretinoin)
Retin-A/Retin-A Micro (tretinoin)
Botox (botulinium toxin type A)
Outlook for the skin aging market
Pipeline analysis focus on Allergan
Appendix
References
Index

List of Figures
Figure 1.1: Do you have a lifestyle drug?: summary search engine
Figure 1.2: Segmentation of the global lifestyle drug market by indication, 2002
Figure 1.3: Larger sales forces are no more efficient at revenue generation than smaller sales forces
Figure 1.4: Average annual growth rates of the total population and the population in broad age
groups, by major area, 2000-50 (median variant)
Figure 1.5: Real household disposable income per head- and gross domestic product per head in the UK, 1971-2001
Figure 1.6: US DTC marketing investment, 1996-2002
Figure 1.7: Consumers are motivated to seek health-related information and empowered by the multiple sources available to them
Figure 1.8: Perceived or otherwise, differences between consumer and pharma brands have previously hindered investment in pharma branding
Figure 1.9: The reimbursement decision process
Figure 1.10: Improving reimbursement status of lifestyle drugs: a three-pronged approach
Figure 2.11: Forecast growth of the global depression market, 2002-08 79
Figure 3.1: Global forecasts of leading companies’ oral contraceptives to 2008 106
Figure 4.1: Prevalence of male sexual dysfunction, 2002 134
Figure 4.2: Prevalence of female sexual dysfunction within the general population, 2002
Figure 4.3: Obstacles to female sexual dysfunction presentation: patient, physician and system variables

List of Tables
Table 1.1: Adoption of economic evaluation in healthcare decision-making in selected major economies
Table 2.2: Symptoms of depression and mania
Table 2.3: Adult depression prevalence rate, 2002
Table 2.4: Forecast growth of the global depression market, 2002-08
Table 2.5: Global forecasts of leading and new antidepressants to 2008
Table 2.6: Depression pipeline, phase II and above
Table 3.7: Forecast growth of the childbearing population, 2003-07 (000s)
Table 3.8: Estimated size of the hormonal contraceptive using population
Table 3.9: Global forecasts of leading companies’ oral contraceptives to 2008
Table 4.10: Common physiological causes of erectile dysfunction
Table 4.11: Prevalence of male sexual dysfunction, 2002 (000s)
Table 4.12: Prevalence of complete and severe erectile dysfunction in the over 40s, 2002 (000s)

Table 4.13: Current treatment options for erectile dysfunction
Table 4.14: Global forecasts of leading and innovative erectile dysfunction drugs to 2008
Table 4.15: Male sexual dysfunction pipeline, phase II and above
Table 4.16: Prevalence of female sexual dysfunction within the general population, 2002 (000s)
Table 4.17: The female sexual dysfunction pipeline, phase II and above
Table 4.18: Forecast sales of late stage products to treat female sexual dysfunction, 2004-08